Bristol-Myers Squibb Company

BMV:BMY * Stock Report

Market Cap: Mex$2.4t

Bristol-Myers Squibb Valuation

Is BMY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BMY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
Mex$2.85k
Fair Value
58.4% undervalued intrinsic discount
21
Number of Analysts

Below Fair Value: BMY * (MX$1184.9) is trading below our estimate of fair value (MX$2845.07)

Significantly Below Fair Value: BMY * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMY *?

Key metric: As BMY * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BMY *. This is calculated by dividing BMY *'s market cap by their current revenue.
What is BMY *'s PS Ratio?
PS Ratio2.5x
SalesUS$47.44b
Market CapUS$119.95b

Price to Sales Ratio vs Peers

How does BMY *'s PS Ratio compare to its peers?

The above table shows the PS ratio for BMY * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.1x
LAB B Genomma Lab Internacional. de
1.5x9.9%Mex$25.5b
SAN Sanofi
2.6x4.5%€124.6b
ZTS Zoetis
8.2x5.7%US$75.2b
NOVN Novartis
4x2.1%CHF 180.5b
BMY * Bristol-Myers Squibb
2.5x-3.5%Mex$119.9b

Price-To-Sales vs Peers: BMY * is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (4.1x).

Price to Sales Ratio vs Industry

How does BMY *'s PS Ratio compare vs other companies in the Global Pharmaceuticals Industry?

183 CompaniesPrice / SalesEstimated GrowthMarket Cap
No. of Companies183PS02.44.87.29.612+
183 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BMY * is expensive based on its Price-To-Sales Ratio (2.5x) compared to the Global Pharmaceuticals industry average (2.5x).

Price to Sales Ratio vs Fair Ratio

What is BMY *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMY * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMY *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BMY * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentMex$1,184.90
Mex$1,243.69
+5.0%
12.3%Mex$1,488.21Mex$795.07n/a21
Jan ’26Mex$1,197.69
Mex$1,227.02
+2.4%
12.1%Mex$1,470.56Mex$785.64n/a21
Dec ’25Mex$1,222.00
Mex$1,230.58
+0.7%
12.0%Mex$1,486.44Mex$794.13n/a21
Nov ’25Mex$1,105.00
Mex$1,105.19
+0.02%
12.4%Mex$1,297.70Mex$729.96n/a22
Oct ’25Mex$1,013.00
Mex$1,061.23
+4.8%
14.7%Mex$1,477.68Mex$728.99n/a21
Sep ’25Mex$980.00
Mex$1,050.28
+7.2%
14.9%Mex$1,476.80Mex$728.56n/a21
Aug ’25Mex$908.77
Mex$975.30
+7.3%
16.2%Mex$1,406.34Mex$693.79n/a22
Jul ’25Mex$767.30
Mex$897.90
+17.0%
16.7%Mex$1,265.96Mex$624.54n/a22
Jun ’25Mex$695.00
Mex$897.90
+29.2%
16.7%Mex$1,265.96Mex$624.54n/a22
May ’25Mex$758.75
Mex$911.18
+20.1%
15.8%Mex$1,276.34Mex$629.66n/a23
Apr ’25Mex$885.00
Mex$936.11
+5.8%
13.3%Mex$1,242.63Mex$679.30n/a23
Mar ’25Mex$860.00
Mex$967.75
+12.5%
15.8%Mex$1,450.66Mex$699.73n/a22
Feb ’25Mex$825.50
Mex$1,040.38
+26.0%
16.7%Mex$1,457.82Mex$720.33n/a23
Jan ’25Mex$867.51
Mex$1,051.57
+21.2%
16.5%Mex$1,443.50Mex$713.26Mex$1,197.6923
Dec ’24Mex$852.00
Mex$1,097.18
+28.8%
17.0%Mex$1,539.70Mex$855.39Mex$1,222.0024
Nov ’24Mex$921.36
Mex$1,168.56
+26.8%
16.0%Mex$1,603.11Mex$890.62Mex$1,105.0023
Oct ’24Mex$1,012.00
Mex$1,241.20
+22.6%
13.0%Mex$1,541.35Mex$941.94Mex$1,013.0023
Sep ’24Mex$1,050.00
Mex$1,241.72
+18.3%
13.4%Mex$1,534.48Mex$954.79Mex$980.0024
Aug ’24Mex$1,034.03
Mex$1,225.83
+18.5%
13.6%Mex$1,540.48Mex$937.69Mex$908.7724
Jul ’24Mex$1,090.12
Mex$1,342.83
+23.2%
12.4%Mex$1,571.04Mex$1,007.51Mex$767.3022
Jun ’24Mex$1,116.00
Mex$1,408.26
+26.2%
12.4%Mex$1,639.02Mex$1,051.11Mex$695.0021
May ’24Mex$1,200.00
Mex$1,411.66
+17.6%
11.8%Mex$1,649.43Mex$1,057.79Mex$758.7521
Apr ’24Mex$1,236.22
Mex$1,447.84
+17.1%
11.4%Mex$1,719.41Mex$1,122.14Mex$885.0021
Mar ’24Mex$1,272.00
Mex$1,545.37
+21.5%
10.9%Mex$1,802.06Mex$1,176.08Mex$860.0019
Feb ’24Mex$1,327.69
Mex$1,527.07
+15.0%
11.0%Mex$1,788.80Mex$1,129.77Mex$825.5019
Jan ’24Mex$1,408.25
Mex$1,576.21
+11.9%
10.9%Mex$1,818.74Mex$1,186.13Mex$867.5119
Analyst Price Target
Consensus Narrative from 21 Analysts
Mex$1.22k
Fair Value
3.1% undervalued intrinsic discount
21
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 19:40
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bristol-Myers Squibb Company is covered by 50 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Ishan MajumdarBaptista Research
Charles ButlerBarclays